Beta Pharma Shanghai

Quick facts

Phase 3 pipeline

• BPI-7711 · Oncology
  BPI-7711 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.